Prediction of Clinical Response and Outcome in Uterine Cervix Cancer

Maastricht Radiation Oncology100 enrolled

Overview

Observational study based on the routine clinical treatment and diagnostic course, to correlate imaging features with outcome objectives. Outcome will evaluated as clinical response to the standard treatment and as recurrence and survival in the follow up. The study hypothesis is that data extracted form FDG-PETCT used in the routine clinical practice can predict outcomes following standard treatment.

This study will prospectively collect patients undergoing to the standard diagnostic and treatment protocol in Maastro Clinic. Any difference in the normal procedure will be adopted. The aim is to extrapolate form the PET images some features of the metabolic tumor activity to associate with different outcomes and tumor behaviours.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Cervix Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed cervix carcinoma (all subtypes) * Tumor Stages FIGO IB - IVA * Scheduled for primary curative radiotherapy (either or not combined with chemotherapy or hyperthermia) * pre treatment FDG PETCT * The patient is willing and capable to comply with study procedures * 18 years or older * Written informed consent to the treatment Exclusion Criteria: * Recent (\< 3 months) myocardial infarction * Uncontrolled infectious disease * Pregnant or breast feeding and/or not willing to take adequate contraceptive measures during the study * Previous surgery to the Cervix * Previous radiation to the Cervix

Locations (1)

Philippe Lambin

Maastricht, Limburg, Netherlands

Outcomes

Primary Outcomes

Change of SUV-related tumor characteristics predicting recurrence

* Standard Uptake Value Max (SUV- defined as the ratio of tissue radioactivity concentration (e.g. in MBq/kg=kBq/g) at time t, c(t), and the injected activity ( in MBq) at the time of injection (t=0) divided by the body weight in kg), * Metabolic Volume (MV) calculated in cc:volume of the evaluable metabolic activity on the PET scan calculated in a specific Region of Interest (ROI) semiautomatically delineated on the primary tumor in the uterine Cervix

Time frame: Changes of parameters will be calculated on the pretreatment scan, than in average 2.5 months after the last radiotherapy session, than at least each 6 month for the first 2 years, eventually shortening the interval if clinically needed

Secondary Outcomes

Change of SUV-related tumor characteristics predicting clinical overall response

Time frame: Changes of parameters will be calculated on the pretreatment scan, and in average 2.5 months after the last radiotherapy session.

Radiomics Features

* We will apply a high throughput approach to convert medical images to minable data, where it is hypothesized that it will improve tumor characterization and treatment outcome prediction. * Extracted imaging features consist firstly of global properties, providing information on the first order histogram of voxel intensity values within the tumor VOI. * Local and regional textural features describing patterns and spatial distribution of voxel intensities, are calculated from respectively gray level co-occurrence and gray level run-length matrix representations. Images will be discretized before texture analysis, which allows for a direct comparison of all calculated textural features between patients. Co-occurrence and gray level run-length matrices are determined considering 26-connected voxels (i.e. voxels were considered to be neighbors in all 13 directions in three dimensions) and a distance of 1 between consecutive voxels. Features derived from the co-occurrence and gray

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.